QuickLinks -- Click here to rapidly navigate through this document

As filed with the Securities and Exchange Commission on December 19, 2012

Registration No. 333-            

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933



AbbVie Inc.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)
  32-0375147
(I.R.S. Employer
Identification No.)

1 North Waukegan Road
North Chicago, Illinois 60064

(Address, including zip code, and telephone number, including
area code, of principal executive offices)

ABBVIE 2013 INCENTIVE STOCK PROGRAM
(Full title of the plan)



Laura J. Schumacher, Esq.
Executive Vice President, Business Development
and External Affairs and General Counsel
1 North Waukegan Road
North Chicago, Illinois 60064
(Name and address of agent for service)

Telephone number, including area code, of agent for service: (847) 932-7900



        Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer o   Accelerated filer o   Non-accelerated filer ý
(Do not check if a
smaller reporting company)
  Smaller reporting company o

CALCULATION OF REGISTRATION FEE

               
 
Title of securities
to be registered

  Amount to be
registered(1)

  Proposed maximum
offering price per
share(2)

  Proposed maximum
aggregate offering
price(2)

  Amount of
registration fee(2)

 

Common Stock, par value $0.01

  84,000,000   $33.34   $2,800,560,000   $381,996.38

 

(1)
Pursuant to Rule 416(a) under the Securities Act of 1933, referred to as the Securities Act, this registration statement also covers an indeterminate number of shares of common stock, par value $0.01 per share, referred to as the Common Stock, of AbbVie Inc., referred to as the Registrant, that may be issuable as a result of a stock split, stock dividend or similar transactions under the AbbVie 2013 Incentive Stock Program, referred to as the Plan. 100,000,000 shares of Common Stock are authorized to be issued under the Plan, which will become effective on the date of the distribution of all the outstanding shares of Common Stock by Abbott Laboratories to shareholders of Abbott Laboratories. This Registration Statement is for 84,000,000 of the 100,000,000 shares of Common Stock to be registered under the Plan as the Registrant expects to register 16,000,000 of these shares on a Form S-1 filed December 10, 2012.

(2)
Estimated solely for the purpose of calculating the registration fee, based, in accordance with Rule 457(c) and Rule 457(h) under the Securities Act of 1933, as amended (the "Securities Act"), on the average of the high and low prices for the Common Stock in the "when issued" trading market as reported on the New York Stock Exchange on December 14, 2012.

   



EXPLANATORY NOTE

        This Registration Statement on Form S-8 is being filed for the purpose of registering 84,000,000 shares of common stock, par value $0.01 per share, of AbbVie Inc. issuable pursuant to the AbbVie 2013 Incentive Stock Program.


PART I

        Information required by Part I to be contained in the Section 10(a) prospectus is omitted from this Registration Statement in accordance with Rule 428(b)(1) under the Securities Act, and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I have been or will be delivered to the participants in the Plan as required by Rule 428(b).


PART II

ITEM 3.    INCORPORATION OF DOCUMENTS BY REFERENCE.

        The following documents, which have been filed by the Registrant with the Securities and Exchange Commission, referred to as the Commission, are incorporated herein by reference:

        All documents filed by the Registrant with the Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of this Registration Statement (other than any such documents or portions thereof that are furnished under Item 2.02 or Item 7.01 of a Current Report on Form 8-K, unless otherwise indicated therein, including any exhibits included with such Items), prior to the filing of a post-effective amendment that indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents.

        Any statement contained in this Registration Statement or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained or incorporated by reference herein or in any subsequently filed document which is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

ITEM 4.    DESCRIPTION OF SECURITIES.

        Not applicable.

ITEM 5.    INTERESTS OF NAMED EXPERTS AND COUNSEL.

        Not applicable.

2



ITEM 6.    INDEMNIFICATION OF DIRECTORS AND OFFICERS.

        The Registrant is incorporated under the laws of the State of Delaware.

        Delaware law provides that directors of a corporation will not be personally liable to the corporation or its stockholders for monetary damages for breach of their fiduciary duties as directors, except for liability:

        The limitation of liability does not apply to liabilities arising under the federal or state securities laws and does not affect the availability of equitable remedies, such as injunctive relief or rescission.

        The Registrant's amended and restated certificate of incorporation and by-laws include provisions that indemnify, to the fullest extent allowable under the DGCL, the personal liability of directors or officers for monetary damages for actions taken as a director or officer of the Registrant, or for serving at the Registrant's request as a director or officer or another position at another corporation or enterprise, as the case may be. The Registrant's amended and restated certificate of incorporation and by-laws also provide that the Registrant must indemnify and advance reasonable expenses to its directors and officers, subject to its receipt of an undertaking from the indemnified party as may be required under the DGCL. The Registrant's amended and restated certificate of incorporation expressly authorizes the Registrant to carry directors' and officers' insurance to protect it, its directors, officers and certain employees for some liabilities.

        The foregoing is only a general summary of certain aspects of Delaware law and the Registrant's certificate of incorporation and by-laws dealing with indemnification of directors and officers and does not purport to be complete. It is qualified in its entirety by reference to the detailed provisions of those sections of the DGCL referenced above and the certificate of incorporation and by-laws of the Registrant.

ITEM 7.    EXEMPTION FROM REGISTRATION CLAIMED.

        Not applicable.

ITEM 8.    EXHIBITS.

        The list of exhibits is set forth under "Exhibit Index" at the end of this Registration Statement and is incorporated herein by reference.

ITEM 9.    UNDERTAKINGS.

3


4



SIGNATURES

        The Registrant.    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in North Chicago, Illinois, on December 19, 2012.

ABBVIE INC.    

By:

 

/s/ RICHARD A. GONZALEZ


 

 
    Name:   Richard A. Gonzalez    
    Title:   Chairman of the Board and Chief Executive Officer    


POWER OF ATTORNEY

        Each person whose signature appears below constitutes and appoints Richard A. Gonzalez and Laura J. Schumacher, Esq., and each of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including all pre-effective and post-effective amendments and registration statements filed pursuant to Rule 462 under the Securities Act of 1933), and to file the same with all exhibits thereto, and other documents in connection therewith, with the Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

        Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following persons in their said capacities on December 19, 2012:

Signature
 
Title
 
Date

 

 

 

 

 
/s/ RICHARD A. GONZALEZ

Richard A. Gonzalez
  Chief Executive Officer and Chairman of the Board (Principal Executive Officer)   December 19, 2012

/s/ WILLIAM J. CHASE

William J. Chase

 

Executive Vice President, Chief Financial Officer (Principal Financial Officer)

 

December 19, 2012

/s/ THOMAS A. HURWICH

Thomas A. Hurwich

 

Vice President, Controller and Principal Accounting Officer

 

December 19, 2012

/s/ THOMAS C. FREYMAN

Thomas C. Freyman

 


Director

 

December 19, 2012

/s/ GREG W. LINDER

Greg W. Linder

 


Director

 

December 19, 2012

5



EXHIBIT INDEX

Exhibit
Number
  Description
  4.1   Form of Amended and Restated Certificate of Incorporation of AbbVie Inc. (incorporated by reference to Exhibit 3.1 of Amendment No. 6 to the Company's Registration Statement on Form 10 filed on November 30, 2012, File No. 001-35565).

 

4.2

 

Form of Amended and Restated By-Laws of AbbVie Inc. (incorporated by reference to Exhibit 3.2 of Amendment No. 6 to the Company's Registration Statement on Form 10 filed on November 30, 2012, File No. 001-35565).

 

4.3

 

AbbVie 2013 Incentive Stock Program (incorporated by reference to Exhibit 10.14 of Amendment No. 6 to the Company's Registration Statement on Form 10 filed on November 30, 2012, File No. 001-35565).

 

5.1

 

Opinion of Wachtell, Lipton, Rosen & Katz.*

 

23.1

 

Consent of Deloitte & Touche LLP.*

 

23.2

 

Consent of Wachtell, Lipton, Rosen & Katz (included in Exhibit 5.1).*

*
Filed herewith.

6




QuickLinks

EXPLANATORY NOTE
PART I
PART II
SIGNATURES
POWER OF ATTORNEY
EXHIBIT INDEX

Exhibit 5.1

 

Wachtell, Lipton, Rosen & Katz

 

MARTIN LIPTON

STEPHANIE J. SELIGMAN

51 WEST 52ND STREET

DAVID C. BRYAN

MARTIN J.E. ARMS

HERBERT M. WACHTELL

JOHN F. SAVARESE

NEW YORK, N.Y. 10019-6150

STEVEN A. COHEN

GREGORY E. OSTLING

BERNARD W. NUSSBAUM

SCOTT K. CHARLES

TELEPHONE:    (212) 403 -1000

DEBORAH L. PAUL

DAVID B. ANDERS

LAWRENCE B. PEDOWITZ

DAVID S. NEILL

FACSIMILE:      (212) 403 -2000

DAVID C. KARP

ADAM J. SHAPIRO

PAUL VIZCARRONDO, JR.

JODI J. SCHWARTZ

––––––––––––––––

RICHARD K. KIM

NELSON O. FITTS

PETER C. HEIN

ADAM O. EMMERICH

GEORGE A. KATZ (1965-1989)

JOSHUA R. CAMMAKER

JEREMY L. GOLDSTEIN

HAROLD S. NOVIKOFF

GEORGE T. CONWAY III

JAMES H. FOGELSON (1967-1991)

MARK GORDON

JOSHUA M. HOLMES

KENNETH B. FORREST

RALPH M. LEVENE

––––––––––––––––

JOSEPH D. LARSON

DAVID E. SHAPIRO

MEYER G. KOPLOW

RICHARD G. MASON

OF COUNSEL

LAWRENCE S. MAKOW

DAMIAN G. DIDDEN

THEODORE N. MIRVIS

MICHAEL J. SEGAL

 

 

JEANNEMARIE O’BRIEN

ANTE VUCIC

EDWARD D. HERLIHY

DAVID M. SILK

WILLIAM T. ALLEN

ERIC S. ROBINSON

WAYNE M. CARLIN

IAN BOCZKO

DANIEL A. NEFF

ROBIN PANOVKA

PETER C. CANELLOS

PATRICIA A. ROBINSON*

STEPHEN R. DiPRIMA

MATTHEW M. GUEST

ERIC M. ROTH

DAVID A. KATZ

DAVID M. EINHORN

LEONARD M. ROSEN

NICHOLAS G. DEMMO

DAVID E. KAHAN

ANDREW R. BROWNSTEIN

ILENE KNABLE GOTTS

THEODORE GEWERTZ

MICHAEL W. SCHWARTZ

IGOR KIRMAN

DAVID K. LAM

MICHAEL H. BYOWITZ

DAVID M. MURPHY

RICHARD D. KATCHER

ELLIOTT V. STEIN

JONATHAN M. MOSES

BENJAMIN M. ROTH

PAUL K. ROWE

JEFFREY M. WINTNER

THEODORE A. LEVINE

WARREN R. STERN

T. EIKO STANGE

JOSHUA A. FELTMAN

MARC WOLINSKY

TREVOR S. NORWITZ

DOUGLAS K. MAYER

PATRICIA A. VLAHAKIS

DAVID A. SCHWARTZ

ELAINE P. GOLIN

DAVID GRUENSTEIN

BEN M. GERMANA

ROBERT B. MAZUR

J. BRYAN WHITWORTH

JOHN F. LYNCH

EMIL A. KLEINHAUS

STEPHEN G. GELLMAN

ANDREW J. NUSSBAUM

PHILIP MINDLIN

AMY R. WOLF

WILLIAM SAVITT

KARESSA L. CAIN

STEVEN A. ROSENBLUM

RACHELLE SILVERBERG

ROBERT M. MORGENTHAU

 

ERIC M. ROSOF

 

 

 

 

 

 

 


 

 

* ADMITTED IN THE DISTRICT OF COLUMBIA

 

 

 

 

––––––––––––––––

 

 

 

 

COUNSEL

 

 

 

 

 

 

 

 

 

 

DAVID M. ADLERSTEIN

PAULA N. GORDON

 

 

 

 

MICHELE J. ALEXANDER

NANCY B. GREENBAUM

 

 

 

 

LOUIS J. BARASH

MAURA R. GROSSMAN

 

 

 

 

DIANNA CHEN

MARK A. KOENIG

 

 

 

 

ANDREW J.H. CHEUNG

J. AUSTIN LYONS

 

 

 

 

PAMELA EHRENKRANZ

AMANDA N. PERSAUD

 

 

 

 

KATHRYN GETTLES-ATWA

JEFFREY A. WATIKER

 

 

 

December 19, 2012

 

AbbVie Inc.

1 North Waukegan Road

North Chicago, IL 60064

 

Re:          Registration Statement on Form S-8

 

We have acted as special counsel to AbbVie Inc., a Delaware corporation (the “Company”), in connection with the preparation and filing of the Company’s Registration Statement on Form S-8 (the “Registration Statement”) relating to a total of 84,000,000 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), issuable upon exercise of stock options or otherwise in connection with grants of equity-based awards under the AbbVie 2013 Incentive Stock Program (the “Plan”) to be issued in connection with the distribution by Abbott Laboratories (“Abbott”) of all of the outstanding shares of the Common Stock to shareholders of Abbott (the “Distribution”).

 

In rendering this opinion, we have examined such corporate records and other documents (including the written document constituting the Plan, the Registration Statement and the Company’s certificate of incorporation and by-laws as currently in effect and amendments thereto as contemplated to be in effect at the time of the Distribution), and we have reviewed such matters of law, as we have deemed necessary or appropriate.  In rendering this opinion, we have, with the Company’s consent, relied upon oral and written representations of officers of the Company and certificates of officers of the Company and public officials with respect to the accuracy of the factual matters addressed in such representations and certificates.  In addition, in rendering this opinion we have, with the Company’s consent, assumed the genuineness of all signatures or instruments relied upon by us, and the conformity of certified copies submitted to us with the original documents to which such certified copies relate.  In addition, we have assumed that the Plan will be effective at the time that the Common Stock will be issued and delivered.

 



 

 

December 19, 2012

Page 2

 

We are members of the Bar of the State of New York and we express no opinion as to the laws of any jurisdiction other than the federal laws of the United States, the laws of the State of New York and the General Corporation Law of the State of Delaware.

 

Based on the foregoing and subject to the qualifications and limitations set forth herein, we are of the opinion that upon issuance and delivery pursuant to the terms and conditions set forth in the Registration Statement, the prospectus delivered to participants in the Plan and the Plan, the Common Stock will be legally issued, fully paid and nonassessable.

 

We hereby consent to be named in the Registration Statement and in the related prospectus contained therein as the attorneys who passed upon the legality of the Common Stock and to the filing of a copy of this opinion as Exhibit 5.1 to the Registration Statement.  In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended.  We assume no obligation to advise you or any other person, or to make any investigations, as to any legal developments or factual matters arising subsequent to the date of effectiveness of the Registration Statement that might affect the opinions expressed herein.

 

 

Very truly yours,

 

 

 

/s/ Wachtell, Lipton, Rosen & Katz

 




Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our report relating to the combined financial statements of the Research-Based Pharmaceuticals Business of Abbott Laboratories (“AbbVie”) dated June 4, 2012, appearing in AbbVie Inc.’s Registration Statement on Form 10 (Commission File No. 001-35565) for the year ended December 31, 2011.

 

 

/s/ DELOITTE & TOUCHE LLP

 

Chicago, Illinois

December 19, 2012